Palexia (Tapentadol)

Tapentadol, the active ingredient in Palexia, is an opioid analgesic presented as a strength/form for oral use. It is indicated for the management of moderate to severe acute pain in adult patients when alternative treatments are inadequate. GNH USA supplies Palexia as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Palexia as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Tapentadol is an opioid analgesic that acts on the central nervous system to relieve pain.

- Acute postoperative pain: Provides effective analgesia following surgical procedures. - Chronic musculoskeletal pain: Helps manage persistent pain associated with conditions such as osteoarthritis. - Cancer‑related pain: Used as part of a multimodal regimen for cancer pain management. - Neuropathic pain: May reduce pain intensity in certain neuropathic pain syndromes. - Severe traumatic injury pain: Controls pain after major trauma.

Tapentadol may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea - Constipation - Dizziness - Headache - Somnolence - Dry mouth

Serious or Rare Side Effects: - Respiratory depression - Seizures - Severe hypotension - Anaphylaxis - Addison Syndrome - Stevens‑Stevens ":"    "  """"  """ """

Tapentadol may   g   t  \